Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Advanced equipment targets radiation to specific areas in the brain

Radiation oncologists at Rush University Medical Center are intent on finding ways to avoid damage to the critically important hippocampus and limbic circuit of the brain when cranial radiation is required to treat existing or potential metastatic cancers.

4 Nov 2009

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union is supporting with nearly 10 million euros, was held in fall 2009 in the Department of Radiooncology and Radiation Therapy of the Heidelberg University Hospital.

30 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

UCSF receives $6.5 million gift from philanthropists Irwin and Joan Jacobs of La Jolla

Philanthropists Irwin and Joan Jacobs of La Jolla, CA are giving a $6.5 million gift to UCSF for head and neck cancer research. It is believed to be the largest private, U.S. gift for research supporting this disease.

28 Oct 2009

Liquid-based cytology is not better than Pap tests for detecting cervical cancer

A Dutch study that included nearly 90,000 women finds that liquid-based cytology, a commonly used alternative to conventional Pap tests, is not superior to Pap tests for the detection of cervical cancer precursors or cancer, according to a study in the October 28 issue of JAMA.

28 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009

International experts discuss ion radiation therapy

The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg. Well over 600 international participants, especially from Japan and the USA, convened in the Heidelberg Town Hall for the annual meeting of the "Particle Therapy Cooperative Group" (PTCOG), including leading experts from the fields of radiation therapy, medical physics and oncology.

27 Oct 2009

Some colonoscopic technologies better at improving detection of adenomas

Recent advances in colonoscopic technology are featured in a number of studies presented at the Annual Scientific Meeting of the American College of Gastroenterology this week. In this research some technologies fare better than others at improving detection of potentially pre-cancerous growths in the colon known as adenomas.

27 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.

27 Oct 2009

National campaign to raise awareness of actinic keratosis

Driver Aric Almirola is lending his voice to a national public education program to raise awareness of actinic keratosis (AK) -- a potential early warning sign of skin cancer -- as well as the long-term consequences of sun damage over a lifetime. The national campaign, "Is it AK or OK?" is sponsored by Graceway Pharmaceuticals, LLC, in partnership with The Skin Cancer Foundation.

24 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

Markers that cause primary liver cancer identified

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year.

21 Oct 2009

Carcinoma News and Research

Further Reading

Advanced equipment targets radiation to specific areas in the brain

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

Third-quarter 2009 financial results of Antigenics announced

UCSF receives $6.5 million gift from philanthropists Irwin and Joan Jacobs of La Jolla

Liquid-based cytology is not better than Pap tests for detecting cervical cancer

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

International experts discuss ion radiation therapy

Some colonoscopic technologies better at improving detection of adenomas

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

National campaign to raise awareness of actinic keratosis

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Rosetta Genomics, GTG sign exclusive distribution agreement

Celgene announces fiscal 2009 third-quarter results

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Markers that cause primary liver cancer identified

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News